Ahmed R. Alibrahim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ahmed R. Alibrahim has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Moeber Mohammed Mahzari
College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia
3 shared publications - Awad Alshahrani
King Abdullah International Medical Research Center, Riyadh, Riyadh Region, Saudi Arabia
2 shared publications Waleed Almutairi
2 shared publications- Aamir Omair
King Abdullah International Medical Research Center, Riyadh 11481, Saudi Arabia
1 shared publication - Abdulaziz S. Almadani
College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia
1 shared publication - Abdullah A Alqahtani
Internal Medicine, King Khalid University Hospital, Riyadh, SAU
1 shared publication
Latest Publications
- Open Access
- 16 November 2026
- Published by MDPI AG in Healthcare
- Vol. 14 (22) , 3931
Changes in Glycemic Outcomes Following FreeStyle Libre Initiation Among Individuals with Type 1 Diabetes, Insulin-Intensive Type 2 Diabetes, and Basal Insulin-Treated Type 2 Diabetes: A Retrospective Pre–Post Study in Saudi Arabia
Background/Objectives: Data describing glycemic changes after FreeStyle Libre (FSL) initiation in insulin-treated patients in Saudi Arabia are limited. We compared period-average HbA1c and hospital-recorded acute diabetes events (ADEs) during the 12 months before and after FSL initiation. Methods: This single-center retrospective uncontrolled pre–post cohort included 202 individuals first prescribed FSL between February and July 2023 who had at least three post-initiation sensor dispensing/refill records and no documented discontinuation. The refill criterion selects participants based on follow-up behavior. HbA1c was averaged within each 12-month period. Results: Among 202 participants (70 T1DM, 67 T2DM-MDI, 65 T2DM-Basal), mean HbA1c was 9.1 ± 1.9% before and 8.7 ± 1.8% after initiation (mean within-person change −0.44 percentage points, 95% CI −0.67 to −0.21; paired t-test p < 0.001). Within-group changes were −0.19 (p = 0.318), −0.58 (p = 0.009), and −0.55 (p = 0.008) percentage points in T1DM, T2DM-MDI, and T2DM-Basal, respectively. Between-group differences in change were not significant (ANOVA p = 0.316; Kruskal–Wallis p = 0.137); the common-slope ANCOVA group effect was nonsignificant (F[2, 198] = 1.58, p = 0.208), but the group × baseline HbA1c interaction was significant (F[2, 196] = 4.27, p = 0.015). Exploratory conditional pairwise contrasts at baseline HbA1c levels of 8%, 9% and 10% were not significant after multiplicity adjustment. Exploratory baseline-HbA1c strata were not multiplicity-adjusted and are vulnerable to regression to the mean. ADE counts were sparse. Conclusions: Lower mean HbA1c was observed after FSL initiation among selected patients, particularly in the two T2DM groups within-group; an independent FSL effect cannot be inferred without a comparator or treatment-change information.
- 16 November 2026
- Published by MDPI AG in Healthcare
- Vol. 14 (22) , 3931
Open AccessChanges in Glycemic Outcomes Following FreeStyle Libre Initiation Among Individuals with Type 1 Diabetes, Insulin-Intensive Type 2 Diabetes, and Basal Insulin-Treated Type 2 Diabetes: A Retrospective Pre–Post Study in Saudi Arabia
Background/Objectives: Data describing glycemic changes after FreeStyle Libre (FSL) initiation in insulin-treated patients in Saudi Arabia are limited. We compared period-average HbA1c and hospital-recorded acute diabetes events (ADEs) during the 12 months before and after FSL initiation. Methods: This single-center retrospective uncontrolled pre–post cohort included 202 individuals first prescribed FSL between February and July 2023 who had at least three post-initiation sensor dispensing/refill records and no documented discontinuation. The refill criterion selects participants based on follow-up behavior. HbA1c was averaged within each 12-month period. Results: Among 202 participants (70 T1DM, 67 T2DM-MDI, 65 T2DM-Basal), mean HbA1c was 9.1 ± 1.9% before and 8.7 ± 1.8% after initiation (mean within-person change −0.44 percentage points, 95% CI −0.67 to −0.21; paired t-test p < 0.001). Within-group changes were −0.19 (p = 0.318), −0.58 (p = 0.009), and −0.55 (p = 0.008) percentage points in T1DM, T2DM-MDI, and T2DM-Basal, respectively. Between-group differences in change were not significant (ANOVA p = 0.316; Kruskal–Wallis p = 0.137); the common-slope ANCOVA group effect was nonsignificant (F[2, 198] = 1.58, p = 0.208), but the group × baseline HbA1c interaction was significant (F[2, 196] = 4.27, p = 0.015). Exploratory conditional pairwise contrasts at baseline HbA1c levels of 8%, 9% and 10% were not significant after multiplicity adjustment. Exploratory baseline-HbA1c strata were not multiplicity-adjusted and are vulnerable to regression to the mean. ADE counts were sparse. Conclusions: Lower mean HbA1c was observed after FSL initiation among selected patients, particularly in the two T2DM groups within-group; an independent FSL effect cannot be inferred without a comparator or treatment-change information.
- Open Access
- 1 August 2026
- Published by Elmer Press, Inc. in Journal of Medical Cases
- Vol. 17 (8) , 415-423
Geroderma Osteodysplastica in Two Patients: Clinical, Genetic, and Management Insights
- 1 August 2026
- Published by Elmer Press, Inc. in Journal of Medical Cases
- Vol. 17 (8) , 415-423
Open AccessGeroderma Osteodysplastica in Two Patients: Clinical, Genetic, and Management Insights
- Open Access
- 26 December 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (52) , e46758
Lipid metabolism in type 1 and type 2 diabetes: A comparative cross-sectional study
Types 1 and 2 diabetes mellitus (T1DM and T2DM, respectively) are chronic conditions with distinct pathophysiological mechanisms and clinical manifestations. Dyslipidemia is a common complication in both types, contributing to increased cardiovascular risk. This study aimed to compare the demographic and laboratory characteristics of patients with T1DM and T2DM in Saudi Arabia. We conducted 2 different studies both are retrospective cross-sectional studies that involved 409 T2DM and 509 T1DM patients, respectively. Data were collected from electronic medical records. Clinical characteristics, including diabetes duration, body mass index, hemoglobin A1C levels, and lipid profiles, were analyzed. Statistical comparisons were conducted to identify significant differences between the 2 groups. Patients with T2DM were older (mean age, 58.93 years) than those with T1DM (mean age, 26.15 years). Additionally, substantial demographic differences were observed between the 2 groups. Compared with patients with T2DM, who had hemoglobin A1C levels between 7% to 9%, patients with T1DM had worse glycemic control, with 55.8% of them having such values. Patients with T2DM were more likely to have obesity (63.6%) than those with T1DM (21.8%). Compared with patients with T2DM, those with T1DM had lower triglyceride levels but higher mean low-density lipoprotein, high-density lipoprotein, and total cholesterol levels. A considerably larger proportion of individuals with T2DM had aberrant triglyceride and low high-density lipoprotein levels, indicating a higher incidence of dyslipidemia. Patients with T1DM and T2DM have different clinical characteristics and lipid abnormalities. Patients with T2DM are at higher risk of dyslipidemia and related cardiovascular complications. To reduce cardiovascular risk in patients with diabetes, customized therapies that concentrate on lipid management and glycemic control are necessary. To manage dyslipidemia, further studies are necessary to investigate the underlying mechanisms and develop efficient treatment plans.
- 26 December 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (52) , e46758
Open AccessLipid metabolism in type 1 and type 2 diabetes: A comparative cross-sectional study
Types 1 and 2 diabetes mellitus (T1DM and T2DM, respectively) are chronic conditions with distinct pathophysiological mechanisms and clinical manifestations. Dyslipidemia is a common complication in both types, contributing to increased cardiovascular risk. This study aimed to compare the demographic and laboratory characteristics of patients with T1DM and T2DM in Saudi Arabia. We conducted 2 different studies both are retrospective cross-sectional studies that involved 409 T2DM and 509 T1DM patients, respectively. Data were collected from electronic medical records. Clinical characteristics, including diabetes duration, body mass index, hemoglobin A1C levels, and lipid profiles, were analyzed. Statistical comparisons were conducted to identify significant differences between the 2 groups. Patients with T2DM were older (mean age, 58.93 years) than those with T1DM (mean age, 26.15 years). Additionally, substantial demographic differences were observed between the 2 groups. Compared with patients with T2DM, who had hemoglobin A1C levels between 7% to 9%, patients with T1DM had worse glycemic control, with 55.8% of them having such values. Patients with T2DM were more likely to have obesity (63.6%) than those with T1DM (21.8%). Compared with patients with T2DM, those with T1DM had lower triglyceride levels but higher mean low-density lipoprotein, high-density lipoprotein, and total cholesterol levels. A considerably larger proportion of individuals with T2DM had aberrant triglyceride and low high-density lipoprotein levels, indicating a higher incidence of dyslipidemia. Patients with T1DM and T2DM have different clinical characteristics and lipid abnormalities. Patients with T2DM are at higher risk of dyslipidemia and related cardiovascular complications. To reduce cardiovascular risk in patients with diabetes, customized therapies that concentrate on lipid management and glycemic control are necessary. To manage dyslipidemia, further studies are necessary to investigate the underlying mechanisms and develop efficient treatment plans.
- Open Access
- 19 July 2024
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (29) , e39026
Retinopathy risk factors in patients with type 2 diabetes on liraglutide
Liraglutide, a glucagon-like peptide 1 receptor agonist, effectively treats type 2 diabetes(T2D) by lowering glucose levels, suppressing glucagon release, and promoting insulin secretion. Liraglutide has been shown to reduce body weight and glycated hemoglobin (HbA1c) levels and improve cardiovascular outcomes. However, evidence regarding the association between liraglutide and diabetic retinopathy in the Middle East is insufficient. Therefore, this study aimed to investigate the characteristics and risk factors of diabetic retinopathy in patients with T2D treated with liraglutide in Saudi Arabia. This retrospective cohort study was conducted on patients (≥14 years) with T2D treated with liraglutide between 2015 and 2021, who had a documented retinopathy assessment at baseline before liraglutide initiation and during follow-up, at King Abdulaziz Medical City (KAMC), Riyadh. Data collection included demographic information, retinopathy status, body mass index (BMI), and HbA1c level at baseline and follow-up after liraglutide use. The study included 181 patients with a mean age of 58.2 (9.8) years. Of these, 72.9% were females. At baseline, the median weight (interquartile range) was 88 (77–100) kg, diabetes duration was 19 (13–23.5) years, and HbA1c level was 9% (8–10%). Total of 69.6% were on insulin, 22.7% were on oral hypoglycemic agents, and 7.7% were on no other medications in addition to liraglutide. After a median of 2 years follow-up, both HbA1c level and weight decreased significantly (P < .001). Seventy-one of the 87 patients (81.6%) without retinopathy at baseline continued to show no retinopathy. Among patients with retinopathy at baseline, 25.5% showed improvement and 44.7% showed no change. In the multivariate binary mixed effect analysis, factors significantly associated with retinopathy were: use of insulin (odds ratio [OR]:2.68; 95% confidence interval [CI]: 1.18–6.09, P = .019), older age (OR:1.03; 95% CI: 1.00–1.06; P = .022), higher HbA1c level (OR:1.17; 95% CI: 1.02–1.34; P = .024), Hypertension (OR:2.56; 95% CI: 1.13–5.76; P=<.0001) and longer diabetes duration (OR:1.04; 95% CI: 1.00–1.08; P = .024). In conclusion, liraglutide use caused significant reductions in the HbA1c level and weight of patients with T2D. Most patients showed no change in retinopathy status after liraglutide use.
- 19 July 2024
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (29) , e39026
Open AccessRetinopathy risk factors in patients with type 2 diabetes on liraglutide
Liraglutide, a glucagon-like peptide 1 receptor agonist, effectively treats type 2 diabetes(T2D) by lowering glucose levels, suppressing glucagon release, and promoting insulin secretion. Liraglutide has been shown to reduce body weight and glycated hemoglobin (HbA1c) levels and improve cardiovascular outcomes. However, evidence regarding the association between liraglutide and diabetic retinopathy in the Middle East is insufficient. Therefore, this study aimed to investigate the characteristics and risk factors of diabetic retinopathy in patients with T2D treated with liraglutide in Saudi Arabia. This retrospective cohort study was conducted on patients (≥14 years) with T2D treated with liraglutide between 2015 and 2021, who had a documented retinopathy assessment at baseline before liraglutide initiation and during follow-up, at King Abdulaziz Medical City (KAMC), Riyadh. Data collection included demographic information, retinopathy status, body mass index (BMI), and HbA1c level at baseline and follow-up after liraglutide use. The study included 181 patients with a mean age of 58.2 (9.8) years. Of these, 72.9% were females. At baseline, the median weight (interquartile range) was 88 (77–100) kg, diabetes duration was 19 (13–23.5) years, and HbA1c level was 9% (8–10%). Total of 69.6% were on insulin, 22.7% were on oral hypoglycemic agents, and 7.7% were on no other medications in addition to liraglutide. After a median of 2 years follow-up, both HbA1c level and weight decreased significantly (P < .001). Seventy-one of the 87 patients (81.6%) without retinopathy at baseline continued to show no retinopathy. Among patients with retinopathy at baseline, 25.5% showed improvement and 44.7% showed no change. In the multivariate binary mixed effect analysis, factors significantly associated with retinopathy were: use of insulin (odds ratio [OR]:2.68; 95% confidence interval [CI]: 1.18–6.09, P = .019), older age (OR:1.03; 95% CI: 1.00–1.06; P = .022), higher HbA1c level (OR:1.17; 95% CI: 1.02–1.34; P = .024), Hypertension (OR:2.56; 95% CI: 1.13–5.76; P=<.0001) and longer diabetes duration (OR:1.04; 95% CI: 1.00–1.08; P = .024). In conclusion, liraglutide use caused significant reductions in the HbA1c level and weight of patients with T2D. Most patients showed no change in retinopathy status after liraglutide use.
- Open Access
- 18 October 2023
- Published by Springer Nature in Cureus
- Vol. 15 (10) , e47266
Coexistence of Bilateral Giant Adrenal Myelolipomas and Congenital Adrenal Hyperplasia: A Case Report
Adrenal myelolipomas (AMs) are rare and benign neoplasms, consisting of adipose and mature hematopoietic tissue. They are commonly discovered incidentally with increased use of radiologic imaging. A small number of giant bilateral adrenal masses are reported, particularly in the setting of congenital adrenal hyperplasia (CAH). We report the case of a 36-year-old male with a history of CAH on steroids since childhood, self-discontinued shortly after diagnosis, presenting mainly with abdominal distension and pain besides infertility. Imaging revealed giant bilateral adrenal masses. Subsequently, he underwent bilateral adrenalectomy, and the surgical pathology report revealed myelolipomas measuring 39×17×8 cm on the left and weighing 4050 grams and 28×16×5 cm on the right and weighing 1702 grams. AMs are found to coexist with many other conditions such as Cushing’s syndrome, pheochromocytoma, and CAH. We discuss the association with high adrenocorticotropic hormone (ACTH) states and review the studies involving ACTH as a stimulator leading to myelolipomas. This case report highlights the proper history taking and biochemical evaluation for early detection and intervention to avoid catastrophic consequences.
- 18 October 2023
- Published by Springer Nature in Cureus
- Vol. 15 (10) , e47266
Open AccessCoexistence of Bilateral Giant Adrenal Myelolipomas and Congenital Adrenal Hyperplasia: A Case Report
Adrenal myelolipomas (AMs) are rare and benign neoplasms, consisting of adipose and mature hematopoietic tissue. They are commonly discovered incidentally with increased use of radiologic imaging. A small number of giant bilateral adrenal masses are reported, particularly in the setting of congenital adrenal hyperplasia (CAH). We report the case of a 36-year-old male with a history of CAH on steroids since childhood, self-discontinued shortly after diagnosis, presenting mainly with abdominal distension and pain besides infertility. Imaging revealed giant bilateral adrenal masses. Subsequently, he underwent bilateral adrenalectomy, and the surgical pathology report revealed myelolipomas measuring 39×17×8 cm on the left and weighing 4050 grams and 28×16×5 cm on the right and weighing 1702 grams. AMs are found to coexist with many other conditions such as Cushing’s syndrome, pheochromocytoma, and CAH. We discuss the association with high adrenocorticotropic hormone (ACTH) states and review the studies involving ACTH as a stimulator leading to myelolipomas. This case report highlights the proper history taking and biochemical evaluation for early detection and intervention to avoid catastrophic consequences.
- Open Access
- 24 July 2022
- Published by Springer Nature in Cureus
- Vol. 14 (7) , e27190
The Prevalence of Associated Autoimmune Diseases Among Adults With Type 1 Diabetes Mellitus: A Cross-Sectional Study
The relationship between type 1 diabetes mellitus (T1DM) and other autoimmune diseases has been known; however, the actual prevalence in the adult population nor clinical symptoms has not been determined locally. We aim to determine the prevalence of associated autoimmune diseases (Hashimoto’s thyroiditis, celiac disease (CD), and adrenal insufficiency (AI)) and evaluate the most reporting symptoms and glycemic control assessment, as well as microvascular complications and hypoglycemia episodes. A cross-sectional study of 251 patients with T1DM at the diabetic clinic of King Abdulaziz Medical City in Riyadh (KAMC-RD), Saudi Arabia, was conducted. Autoimmune serologies including thyroid peroxidase (TPO) antibody and tissue transglutaminase IgA (tTG-IgA) antibody were checked with hormonal studies such as thyroid-stimulating hormone (TSH), morning serum cortisol, and short Synacthen test (SST) with duodenal biopsy results all were reviewed if present. Patients were directly interviewed to evaluate for the most common symptoms (including hypoglycemia episodes) for the preceding two weeks. Glycemic control was assessed by measuring glycated hemoglobin (HbA1c). Microvascular complications (i.e., nephropathy and retinopathy) were estimated by looking at the urine albumin/creatinine ratio (ACR) besides the ophthalmology’s visit notes. The mean age was 26.3 ± 7.7 years, and the mean duration of diabetes at the time of data collection was 12.2 ± 7.6 years, whereas the mean HbA1c was 8.9% ± 1.8%. The prevalence of hypothyroidism was 16.3%, and TPO positivity was discovered in 58.6% of the tested patients (n = 70) with equal prevalence among both genders (p = 0.685). tTG-IgA were noticed among 16.4% of the patients (n = 164) without significant difference among gender. Serum cortisol test was performed among 128 patients; 28.1% had suboptimal levels, and 5.5% were deficient. Only four patients (n = 15) had suboptimal responses after SST. Nervousness and anxiety (p < 0.001), fatigue with weakness (p = 0.018), weight gain (p = 0.017), and cold intolerance (p = 0.005) were noted, which were statistically significantly higher among females. Weight gain was statistically significantly higher among the age group of >30 years (p = 0.036). For microvascular complication screening, ACR was collected in 199 (79.2%) participants, with a mean of 27.7 ± 155.9 mg/mmol. Only 10 (5%) patients had microalbuminuria, and 16 (8%) had macroalbuminuria; it was correlated significantly with diabetes duration (p = 0.045). A total of 132 (52.8%) patients were seen by ophthalmology, 28 (21.4%) had nonproliferative diabetic retinopathy (NPDR), and 10 (7.6%) has proliferative diabetic retinopathy (PDR) that significantly correlated with the duration of diabetes (p = 0.027). During patient interviews, 187 (74.5%) reported symptomatic hypoglycemia events that correlated significantly with glycemic control (p = 0.029). Autoimmunity in Saudi adults with type 1 diabetes mellitus was significant with equal prevalence among both genders and age groups with no or slight difference. Clinical manifestations of autoimmunity were higher in women. Diabetes chronicity and poor glycemic control were the major complications; therefore, early glycemic control is advocated. Regular screening for autoimmunity and its complications is recommended for type 1 diabetic patients. Autoimmunity was found almost similar to previous literature.
- 24 July 2022
- Published by Springer Nature in Cureus
- Vol. 14 (7) , e27190
Open AccessThe Prevalence of Associated Autoimmune Diseases Among Adults With Type 1 Diabetes Mellitus: A Cross-Sectional Study
The relationship between type 1 diabetes mellitus (T1DM) and other autoimmune diseases has been known; however, the actual prevalence in the adult population nor clinical symptoms has not been determined locally. We aim to determine the prevalence of associated autoimmune diseases (Hashimoto’s thyroiditis, celiac disease (CD), and adrenal insufficiency (AI)) and evaluate the most reporting symptoms and glycemic control assessment, as well as microvascular complications and hypoglycemia episodes. A cross-sectional study of 251 patients with T1DM at the diabetic clinic of King Abdulaziz Medical City in Riyadh (KAMC-RD), Saudi Arabia, was conducted. Autoimmune serologies including thyroid peroxidase (TPO) antibody and tissue transglutaminase IgA (tTG-IgA) antibody were checked with hormonal studies such as thyroid-stimulating hormone (TSH), morning serum cortisol, and short Synacthen test (SST) with duodenal biopsy results all were reviewed if present. Patients were directly interviewed to evaluate for the most common symptoms (including hypoglycemia episodes) for the preceding two weeks. Glycemic control was assessed by measuring glycated hemoglobin (HbA1c). Microvascular complications (i.e., nephropathy and retinopathy) were estimated by looking at the urine albumin/creatinine ratio (ACR) besides the ophthalmology’s visit notes. The mean age was 26.3 ± 7.7 years, and the mean duration of diabetes at the time of data collection was 12.2 ± 7.6 years, whereas the mean HbA1c was 8.9% ± 1.8%. The prevalence of hypothyroidism was 16.3%, and TPO positivity was discovered in 58.6% of the tested patients (n = 70) with equal prevalence among both genders (p = 0.685). tTG-IgA were noticed among 16.4% of the patients (n = 164) without significant difference among gender. Serum cortisol test was performed among 128 patients; 28.1% had suboptimal levels, and 5.5% were deficient. Only four patients (n = 15) had suboptimal responses after SST. Nervousness and anxiety (p < 0.001), fatigue with weakness (p = 0.018), weight gain (p = 0.017), and cold intolerance (p = 0.005) were noted, which were statistically significantly higher among females. Weight gain was statistically significantly higher among the age group of >30 years (p = 0.036). For microvascular complication screening, ACR was collected in 199 (79.2%) participants, with a mean of 27.7 ± 155.9 mg/mmol. Only 10 (5%) patients had microalbuminuria, and 16 (8%) had macroalbuminuria; it was correlated significantly with diabetes duration (p = 0.045). A total of 132 (52.8%) patients were seen by ophthalmology, 28 (21.4%) had nonproliferative diabetic retinopathy (NPDR), and 10 (7.6%) has proliferative diabetic retinopathy (PDR) that significantly correlated with the duration of diabetes (p = 0.027). During patient interviews, 187 (74.5%) reported symptomatic hypoglycemia events that correlated significantly with glycemic control (p = 0.029). Autoimmunity in Saudi adults with type 1 diabetes mellitus was significant with equal prevalence among both genders and age groups with no or slight difference. Clinical manifestations of autoimmunity were higher in women. Diabetes chronicity and poor glycemic control were the major complications; therefore, early glycemic control is advocated. Regular screening for autoimmunity and its complications is recommended for type 1 diabetic patients. Autoimmunity was found almost similar to previous literature.
- Open Access
- 3 June 2022
- Published by Springer Nature in Cureus
- Vol. 14 (6) , e25622
A Pattern of Lipid Profile Among Saudi Adults With Type 1 Diabetes Mellitus in a Tertiary Hospital: A Retrospective Study
Objective: Dyslipidemia is prevalent in adults living with type 1 diabetes, and it can worsen the presentation of microvascular complications such as retinopathy. This study aims to identify the pattern coupled with the frequency of dyslipidemia in diabetic adults who followed up at different clinics in King Abdulaziz Medical City, Riyadh, and evaluate the associations with demographic and clinical characteristics. Methods: A cross-sectional, retrospective chart review study of 514 adults with type 1 diabetes was conducted in a tertiary health care facility in the central region of Saudi Arabia. Demographics were retrieved by using the implemented electronic medical records. Fasting lipid profile, glycated hemoglobin (HbA1c), and thyroid-stimulating hormone (TSH) levels were checked for all subjects. Results: Five hundred and fourteen (514) subjects aged 18-65 years were studied (mean age: 26.1 ± 7.1 years). There were 318 (62%) females in the sample, and their mean age was significantly different from the mean age of males (p = 0.01). The mean duration of having diabetes was 12.8 ± 6.9 years. The prevalence of lipid abnormalities included abnormal low-density lipoprotein (LDL) (70%), hypercholesterolemia (23%), abnormal high-density lipoprotein (HDL) (8%), and hypertriglyceridemia (5%). Abnormal HDL was significantly higher in males than in females (p=p=0.001). Otherwise, there was no significant association of lipid abnormalities with gender, age, diabetes duration, and weight. Conclusion: The most prevalent lipid abnormality was high LDL cholesterol. Nearly a third of the tested individuals had more than one lipid abnormality. Furthermore, poor glycemic control was linked to abnormal lipid profiles. Consequently, local programs must aim to screen and intervene early to delay and prevent future severe vascular complications related to non-treated dyslipidemia.
- 3 June 2022
- Published by Springer Nature in Cureus
- Vol. 14 (6) , e25622
Open AccessA Pattern of Lipid Profile Among Saudi Adults With Type 1 Diabetes Mellitus in a Tertiary Hospital: A Retrospective Study
Objective: Dyslipidemia is prevalent in adults living with type 1 diabetes, and it can worsen the presentation of microvascular complications such as retinopathy. This study aims to identify the pattern coupled with the frequency of dyslipidemia in diabetic adults who followed up at different clinics in King Abdulaziz Medical City, Riyadh, and evaluate the associations with demographic and clinical characteristics. Methods: A cross-sectional, retrospective chart review study of 514 adults with type 1 diabetes was conducted in a tertiary health care facility in the central region of Saudi Arabia. Demographics were retrieved by using the implemented electronic medical records. Fasting lipid profile, glycated hemoglobin (HbA1c), and thyroid-stimulating hormone (TSH) levels were checked for all subjects. Results: Five hundred and fourteen (514) subjects aged 18-65 years were studied (mean age: 26.1 ± 7.1 years). There were 318 (62%) females in the sample, and their mean age was significantly different from the mean age of males (p = 0.01). The mean duration of having diabetes was 12.8 ± 6.9 years. The prevalence of lipid abnormalities included abnormal low-density lipoprotein (LDL) (70%), hypercholesterolemia (23%), abnormal high-density lipoprotein (HDL) (8%), and hypertriglyceridemia (5%). Abnormal HDL was significantly higher in males than in females (p=p=0.001). Otherwise, there was no significant association of lipid abnormalities with gender, age, diabetes duration, and weight. Conclusion: The most prevalent lipid abnormality was high LDL cholesterol. Nearly a third of the tested individuals had more than one lipid abnormality. Furthermore, poor glycemic control was linked to abnormal lipid profiles. Consequently, local programs must aim to screen and intervene early to delay and prevent future severe vascular complications related to non-treated dyslipidemia.
- Open Access
- 14 May 2022
- Published by Springer Nature in Cureus
- Vol. 14 (5) , e24989
A Successful Conservative Management of Spontaneous Adrenal Hemorrhage (SAH) in Pregnancy: A Case Report
It Is well known that abdominal pain during pregnancy has a broad differential diagnosis, which includes spontaneous adrenal hemorrhage (SAH), a rarely reported phenomenon in the literature, defined as an acute hemorrhage into the adrenal gland during pregnancy in the absence of a clear cause. Physicians should have a high suspicion for it due to the potentially life-threatening complications, as they present usually with a non-specific presentation. We present a case of symptomatic SAH in the third trimester of pregnancy that was successfully managed conservatively.
- 14 May 2022
- Published by Springer Nature in Cureus
- Vol. 14 (5) , e24989
Open AccessA Successful Conservative Management of Spontaneous Adrenal Hemorrhage (SAH) in Pregnancy: A Case Report
It Is well known that abdominal pain during pregnancy has a broad differential diagnosis, which includes spontaneous adrenal hemorrhage (SAH), a rarely reported phenomenon in the literature, defined as an acute hemorrhage into the adrenal gland during pregnancy in the absence of a clear cause. Physicians should have a high suspicion for it due to the potentially life-threatening complications, as they present usually with a non-specific presentation. We present a case of symptomatic SAH in the third trimester of pregnancy that was successfully managed conservatively.